Opicapone

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 177 publications

Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study.

Real-World Use of Opicapone in Management of Patients with Parkinson's Disease and Early Motor Fluctuations in Spain: 12-Month Interim Analysis of REONPARK Study.

Journal: Brain sciences

Published: July 28, 2026

The safety and tolerability of opicapone in elderly Parkinson's disease patients: a real-world, multicenter, retrospective study.

The safety and tolerability of opicapone in elderly Parkinson's disease patients: a real-world, multicenter, retrospective study.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: July 06, 2026

German Delphi consensus: COMT inhibitors in the management of wearing-off fluctuations in Parkinson's disease.

German Delphi consensus: COMT inhibitors in the management of wearing-off fluctuations in Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: June 27, 2026

Long-term safety profile of opicapone in patients with Parkinson's disease and early fluctuations.

Long-term safety profile of opicapone in patients with Parkinson's disease and early fluctuations.

Journal: Frontiers in neurology

Published: June 26, 2026

Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database.

Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database.

Journal: Clinical parkinsonism & related disorders

Published: June 19, 2026

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Journal: Journal of Parkinson's disease

Published: April 17, 2026

Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.

Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.

Journal: Brain sciences

Published: March 21, 2026

Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.

Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study.

Journal: Annals of medicine

Published: March 05, 2026

Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease.

Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease.

Journal: Movement disorders clinical practice

Published: February 20, 2026

Recent Developments in the Drug Treatment of Parkinson's Disease.

Recent Developments in the Drug Treatment of Parkinson's Disease.

Journal: Drugs

Published: January 15, 2026

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment

Journal: Zeitschrift fur Gerontologie und Geriatrie

Published: December 19, 2025

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors.

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: December 15, 2025

Showing 1-12 of 177

Last Updated: 11/08/2026